Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Equivalents (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Cash & Equivalents readings, the most recent being $9.1 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 5.81% to $9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 5.81% decrease, with the full-year FY2025 number at $9.1 million, down 5.81% from a year prior.
  • Cash & Equivalents hit $9.1 million in Q4 2025 for Sunshine Biopharma, down from $9.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $41.7 million in Q2 2022 to a low of $1.7 million in Q2 2021.
  • Median Cash & Equivalents over the past 5 years was $11.9 million (2024), compared with a mean of $14.4 million.
  • Biggest five-year swings in Cash & Equivalents: surged 16522.83% in 2021 and later plummeted 53.53% in 2023.
  • Sunshine Biopharma's Cash & Equivalents stood at $2.0 million in 2021, then skyrocketed by 967.22% to $21.8 million in 2022, then fell by 25.35% to $16.3 million in 2023, then plummeted by 40.55% to $9.7 million in 2024, then dropped by 5.81% to $9.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $9.1 million (Q4 2025), $9.3 million (Q3 2025), and $10.3 million (Q2 2025) per Business Quant data.